Teva rises as FDA accepts to review biosimilar to eye disease drug Eylea

Alvotech SA

18/02/2025 13:00

** U.S.-listed shares of Israel-based drugmaker Teva
Pharmaceutical Industries  TEVA.TA   TEVA.N  rises 6.6% to
$17.32 premarket
    ** TEVA and partner Biotech Alvotech  ALVO.O  say the U.S.
FDA has accepted for review its marketing application for a
biosimilar or close copy of Regeneron's  REGN.O  Eylea 
    ** Co says AVT06 is a proposed biosimilar of Eylea's 2
milligram dose which is used to treat eye disorders like macular
degeneration, macular edema and retinopathy
    ** Co, ALVO expects regulatory decision for AVT06 by Q4 2025
    ** Some key patents of Eylea are set to expire in 2027,
according to a regulatory filing
    ** ALVO is also developing AVT29, a biosimilar for Eylea HD,
a 8 mg dose of the drug 
    ** Amgen  AMGN.O  will also make its biosimilar version of
Eylea available to patients after a U.S. appeals court rejected
REGN's request to block its launch 
    ** In the last 12 months, TEVA has risen 32.4%

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))